Healio

Skyrizi 150 mg injection available for plaque psoriasis

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Skyrizi is now available as a single-dose 150 mg ...
Nasdaq

SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis

- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ...
Monthly Prescribing Reference

Skyrizi Now Available as a Single-Dose Injection for Plaque Psoriasis

Skyrizi ® (risankizumab-rzaa) is now available as a single-dose 150mg prefilled pen or syringe for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic ...
Nasdaq

U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis

- SKYRIZI® (risankizumab-rzaa) met the primary endpoint of ACR20 at week 24 in two pivotal studies, demonstrating significant improvement in joint symptoms, including swollen, tender and painful ...

J&J’s new psoriasis pill to rival AbbVie’s Skyrizi: BNP Paribas

AbbVie (ABBV) fell ~4% on Wednesday as BNP Paribas argued that its immunology blockbuster Skyrizi could face competition from Icotyde, a newly approved plaque psoriasis pill developed by Johnson & ...

Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi

Protagonist's pipeline leverages its proprietary Vectrix platform to target obesity, hematology, and inflammation. Find out ...
Seeking Alpha

U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease

NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ -- AbbVie (ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately to ...
FiercePharma

AbbVie's Skyrizi nabs psoriatic arthritis nod, its 2nd, shortly after Rinvoq

After Rinvoq won two new indications in as many months, AbbVie's immunology compatriot Skyrizi is getting in on the approval action. Skyrizi clinched a second nod, this time to treat adults with ...
BioPharma Dive

J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections

The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
Reuters

AbbVie sees strong 2022 earnings as Botox, Skyrizi power profit beat

Feb 2 (Reuters) - AbbVie Inc (ABBV.N), opens new tab forecast full-year adjusted profit above Wall Street estimates on Wednesday, as strong sales of its blockbuster anti-wrinkle injection Botox and ...
The Motley Fool

AbbVie Takes Another Step Toward Its Post-Humira Future

Skyrizi has demonstrated its efficacy in treating patients with psoriatic arthritis. If approved for use in the E.U., psoriatic arthritis could be a blockbuster indication for the drug. AbbVie is a ...